Pharma channel feed

Trump ad­min­is­tra­tion preps ex­ec­u­tive or­der on price trans­paren­cy as law­mak­ers con­verge — WSJ

6 years ago

Novo­cure bags mesothe­lioma nod for elec­tric fields can­cer ther­a­py with some lim­i­ta­tions

6 years ago

Sobered by mount­ing costs, Dy­navax looks to un­load I/O, slash jobs and cir­cle wag­ons around Hep­lisav

6 years ago
People
R&D

Dai­ichi Sankyo re­port­ed­ly sell­ing OTC unit for $900M in piv­ot to on­col­o­gy — but com­pa­ny says it's 'in­cor­rec­t'

6 years ago

In a change of plans, Nek­tar spins out its opi­oid in­to a new biotech sub­sidiary as FDA PDU­FA date looms

6 years ago

In a re­mote Ver­mont ski town, 3 ex­ecs raised $93M for a stem cell re­search cam­pus. Pros­e­cu­tors say it was all just a scam

6 years ago

Sarep­ta's Ex­ondys 51 is not cost-ef­fec­tive, nor par­tic­u­lar­ly ben­e­fi­cial for DMD pa­tients — ICER

6 years ago
R&D

No­var­tis chief Vas Narasimhan wants you to know about the '25-plus’ block­busters he has in the pipeline

6 years ago
R&D

An­oth­er Eli Lil­ly on­col­o­gy drug is in trou­ble, as Japan is­sues Verzenio safe­ty warn­ing

6 years ago

Drug reg­u­la­tors look to har­mo­nize how they tack­le in­no­va­tion

6 years ago
R&D
FDA+

Roche's Chugai to set up new $1B+ lab in Yoko­hama, con­sol­i­dat­ing R&D

6 years ago
R&D

Thanks to Supreme Court de­ci­sion, Mer­ck gets an­oth­er chance to throw out Fos­amax claims

6 years ago

Google's life sci­ences sis­ter plugs Big Phar­ma in­to the main­stream in a dig­i­tal over­haul of the clin­i­cal tri­al busi­ness

6 years ago

BioCryst shares are blast­ed as a PhI­II HAE 'suc­cess' un­der­whelms an­a­lysts

6 years ago
R&D

Be­lea­guered Bio­gen faces the mu­sic as a ris­ing cho­rus of crit­ics push for a trans­for­ma­tive ap­proach to M&A

6 years ago
Deals

Mer­ck bets $2.2B on a small can­cer drug biotech, snatch­ing it out of the IPO line­up

6 years ago
Deals
R&D

Mer­ck­'s Keytru­da fails triple neg­a­tive breast can­cer piv­otal study

6 years ago

TRC Cap­i­tal's mi­ni-ten­der of­fer ir­ri­tates a flus­tered Bio­gen

6 years ago

Can­cer re­search groups urge FDA to over­haul stan­dards for ear­ly cell ther­a­py tri­als, cut­ting time and cost. But will 'pre-com­pet­i­tive' al­liances fly?

6 years ago
R&D
Cell/Gene Tx

Un­der fire for Tru­va­da US pric­ing at House hear­ing, Gilead chief O'­Day touts R&D costs, as­serts gov­ern­ments patents are void

6 years ago

EMA im­pos­es for­mal lim­it on Xel­janz pre­scrip­tion as reg­u­la­tors con­tin­ue to re­view safe­ty con­cerns

6 years ago

Fol­low­ing its lat­est set­back, Achillion posts some en­cour­ag­ing PoC da­ta for lead drug

6 years ago
R&D

Take­da, Fra­zier cre­ate Phath­om Phar­ma­ceu­ti­cals to spur de­vel­op­ment of GI drug vono­prazan in $140M play

6 years ago

Four years af­ter EU ap­proval, NICE fi­nal­ly backs Revlim­id use in cer­tain first-line mul­ti­ple myelo­ma pa­tients

6 years ago
First page Previous page 268269270271272273274 Next page Last page
A service from the Financial Times